Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

Stanford University

Status and phase

Completed

Phase 2

Conditions

Weber-Cockayne Syndrome

Epidermolysis Bullosa Simplex Kobner

Epidermolysis Bullosa Simplex

Treatments

Drug: Vehicle

Drug: Sirolimus, 2%

Study type

Interventional

Funder types

Other

Identifiers

NCT02960997

35498

Details and patient eligibility

About

Epidermolysis bullosa (EB) simplex is a rare orphan disease caused by a mutation in DNA leading to abnormal dominant keratins in the skin. Patients with EB simplex develop lifelong painful thick soles on their feet, and current standard of care is supportive. This pilot study will target the dominant mutant keratin proteins in the skin to ameliorate the severity of EB simplex. The purpose is to improve the function of EB simplex feet with an application of topical sirolimus, 2%. The investigators plan on inhibiting the mTOR pathway to down regulate the translation of defective keratin proteins and work through anti proliferative pathways.

Full description

The proposed 40 week pilot study being conducted is a prospective, double-blind, randomized, placebo-controlled crossover study. Participants will be assigned to treat both feet with either topical sirolimus, 2% cream daily or placebo (vehicle-control) for 12 weeks, followed by a 4 week washout period, then re-treatment to both feet will occur by the cross-over intervention.

These studies will exploit the naturally occurring transcriptional regulation of keratin sequences, the known gene aberration causing EB simplex, and assess the potential for mTOR pathway inhibition in treatment of the patient's plantar lesions. The objective of this study is to assess (1) the safety of topical rapamycin for plantar lesions for the treatment of EB simplex, and 2) test if topical rapamycin to improves the clinical severity of lesional skin, including pain and itch, in subjects with EB simplex at the end of treatment versus baseline and compared to an intrasubject placebo treated control. Wound size measurement, quality of life evaluation will be assessed using epidermolysis bullosa (QOLEB), and EB disease activity and Scarring Index (EBDASI). With the results of this pilot study, physicians would be able to transition from supportive care (the current state of the art for EB simplex) to targeted molecular therapeutics, leading to improved mobility and quality of life for patients with EB simplex.

Enrollment

8 patients

Sex

All

Ages

4+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects must:

Be capable of understanding the purpose and risks of the study and sign a written Informed Consent Form (ICF); Legally authorized representative of subjects willing and able to give consent for children 4-18 yo.
Be male or female with a diagnosis of EBS
Minimum EBDASI feet activity score of 2/10
Age - 4 years or older
Ability to complete 12 study visits within a 40-week period, each for approximately 30-60 minutes.
Anticipated life expectancy ≥52 weeks.
Males and females of childbearing potential should be using an effective means of contraception.
Laboratory values within the range of normal for the participating institution unless the PI feels they are not clinically relevant
Be able to comply with all study requirements

Exclusion criteria

Allergy to sirolimus or components of the vehicle ointment
Pregnancy, breast feeding
Prior history of liver disease
Serious known concurrent medical illness or infection, which could potentially present a safety risk and/or prevent compliance with the requirements of the treatment program.
Known immunodeficiency virus or syndrome including those with:
- Acquired Immunodeficiency Syndrome (AIDS)
- Human Immunodeficiency Virus (HIV)
- Hepatitis B
Prior history of grafting surgeries or other surgeries in the dermatologic treatment area
History of significant condition in the dermatologic treatment area such as trauma, which could impair evaluation for the treatment of EBS or non-healing chronic wound.
Use of other investigational drugs within 30 days of the screening visit and/or has not recovered from any side effects of prior investigational drugs or procedure in the affected area (e.g., a biopsy).
Use of acitretin within the last 1 month
Use of Roaccutane within last 3 months
Botox injections to the feet within the last 6 months.
Participant is planning extra physical activities within the next 3 months.
Amputated foot